Blog

Editas Medicine Announces First Quarter 2018 Results and Update – GlobeNewswire (press release)


Macon Daily

Editas Medicine Announces First Quarter 2018 Results and Update
GlobeNewswire (press release)
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the
BeyondSpring (BYSI) vs. Editas Medicine (EDIT) Head to Head AnalysisBangaloreWeekly



all 36 news articles »

2018-05-03 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.